EQRx, Inc.

NasdaqGM:EQRX Stock Report

Market Cap: US$1.1b

EQRx Valuation

Is EQRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EQRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EQRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EQRX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EQRX?

Key metric: As EQRX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for EQRX. This is calculated by dividing EQRX's market cap by their current book value.
What is EQRX's PB Ratio?
PB Ratio1x
BookUS$1.17b
Market CapUS$1.14b

Price to Book Ratio vs Peers

How does EQRX's PB Ratio compare to its peers?

The above table shows the PB ratio for EQRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average46.7x
RCKT Rocket Pharmaceuticals
3.9x55.2%US$1.3b
APLT Applied Therapeutics
169.2x42.1%US$1.2b
ARQT Arcutis Biotherapeutics
8.7x72.4%US$1.3b
CDNA CareDx
4.9x95.0%US$1.3b
EQRX EQRx
1xn/aUS$1.1b

Price-To-Book vs Peers: EQRX is good value based on its Price-To-Book Ratio (1x) compared to the peer average (1.5x).

Price to Book Ratio vs Industry

How does EQRX's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$588.69m
AMRN Amarin
0.4x-7.7%US$205.50m
IMAB I-Mab
0.4x1.8%US$77.18m
MGX Metagenomi
0.3x-23.2%US$75.22m
EQRX 1.0xIndustry Avg. 1.9xNo. of Companies73PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: EQRX is good value based on its Price-To-Book Ratio (1x) compared to the US Biotechs industry average (1.5x).

Price to Book Ratio vs Fair Ratio

What is EQRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EQRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate EQRX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.4%

1Y

20.0%

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.57

7D

-2.7%

1Y

71.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$59.39

7D

7.8%

1Y

20.6%